Task order 75N93022F00001 base award
Ended Awarded Last action
- Contract number
- 75N93022F00001
- Awardee
-
Allucent Government Services (Us) LLC UEI C7DJDL6EZT94
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $550,536
Award facts
- Opportunity
-
- Early Phase Clinical Trial Units (EPCTU) Pre-Solicitation · 75N93020R00023 · Posted Nov 19, 2020
- Contract value 36% obligated
-
- $550,536.00 Current, with exercised options
- $1,508,562.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Houston, TX 77060, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $143,797 | |
| Exercise an Option | $139,606 | |
| Exercise an Option | $135,540 | |
| Original award | $131,593 |
About this award
This federal contract award is for Task Order 75N93022F00001 under the Early Phase Clinical Trial Units (EPCTU) Indefinite Delivery/Indefinite Quantity (IDIQ) contract, which was awarded to Allucent Government Services (Us) LLC, a for-profit clinical research organization. The task order has a ceiling value of $1,508,562.00 and a period of performance through January 13, 2032. The contract is a Cost Plus Fixed Fee type and was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS). The contract does not have a set-aside designation. Allucent will provide support for early-phase clinical trials, including planning, assay development, manufacturing, and regulatory activities, to advance the development of medical countermeasures against various threats such as infectious diseases, chemical, biological, radiological, and nuclear events, as well as pandemic influenza. This award is part of Allucent's broader portfolio of federal contracts supporting medical research and preparedness efforts across HHS and the Department of Defense.
Quick answers
Who was awarded contract 75N93022F00001?
75N93022F00001 was awarded to Allucent Government Services (Us) LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 14, 2022.
How much is contract 75N93022F00001 worth?
The government has obligated $550,536 on 75N93022F00001. Its potential value, with all options, is $1,508,562.
Is contract 75N93022F00001 an order under another contract?
Yes. 75N93022F00001 is a delivery order under 75N93022D00015, an indefinite delivery contract, on Early Phase Clinical Trial Units (EPCTU).
Was contract 75N93022F00001 competed?
The extent of competition for 75N93022F00001 was full and open competition. The government received 6 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award